靶向CXCR4的抗HIV治疗开发策略与进展
本综述聚焦于靶向趋化因子受体CXCR4的抗HIV治疗策略与研究进展。HIV-1以CD4为主要受体、CXCR4或CCR5为辅受体进入宿主细胞。尽管靶向CCR5或逆转录酶、蛋白酶的抗HIV药物已长期用于临床,但靶向CXCR4的药物尚未推进至临床应用。文中重点汇总了靶向CXCR4的小分子、肽类及大分子药物的发现策略与研究进展,并讨论其作为新型抗HIV疗法转化至临床的前景。
要点
- HIV-1以CD4为主要受体,CXCR4或CCR5为辅受体进入宿主细胞。
- 靶向CCR5、逆转录酶或蛋白酶的抗HIV药物已长期用于临床。
- 靶向CXCR4的抗HIV药物尚未推进至临床应用。
核心结论
- 靶向CXCR4的小分子、肽类及大分子药物是抗HIV治疗的新方向,但尚未进入临床应用。
研究设计与样本
- 综述:汇总靶向CXCR4的小分子、肽类及大分子药物的发现策略与研究进展。
主要发现
- HIV-1通过CD4主要受体及CXCR4或CCR5辅受体进入并感染宿主细胞,并利用细胞内机制复制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The acquired immunodeficiency syndrome (AIDS), caused by the human immunodeficiency virus (HIV), has been a global public health challenge for several decades. The majority of HIV infection is caused by the human immunodeficiency virus type 1 (HIV-1), which enters and infects a host cell via the cell surface proteins of CD4 as the primary receptor, and chemokine receptors CXCR4 or CCR5 as the coreceptor-then undergoing replication using the cell's intracellular machinery. Whereas many drugs targeting CCR5-mediated entry or HIV-1 replication via reverse transcriptase or proteases have long been used clinically, agents targeting CXCR4 are yet to be advanced to clinical application. Here in this review we highlight some of the strategies for and progress made in the discovery of novel small molecules, peptides, and larger molecules that target CXCR4, and their future prospects for translation into the clinic as a new class of anti-HIV therapeutics.
引用
- Huang LSM, Snyder EY, Schooley RT, et al. Strategies and Progress in CXCR4-Targeted Anti-Human Immunodeficiency Virus (HIV) Therapeutic Development. Clin Infect Dis. 2021. PMID: 33624027. doi:10.1093/cid/ciab160
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。